
Sign up to save your podcasts
Or


Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, by Pharma Now, we look at a draft rule from India’s Health Ministry that would suspend a drug factory’s licence the moment its medicine fails one of five key quality tests. Today, a failed lab report leads to a notice, a reply and a wait, and the medicine can stay on shelves in the meantime. We explain what the draft says, why the ministry wants to change this, and why some may worry about acting on a single lab result. We also look at why the solvents used in syrups are getting a paperwork trail of their own.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, by Pharma Now, we look at an antibiotic that, according to its maker Wockhardt, is the first new medicine fully discovered and developed by an Indian company to be approved by the US FDA. It is designed for serious infections caused by bacteria that resist many existing antibiotics, a growing problem known as antimicrobial resistance. We explain how the medicine works, what its trial showed, and why one new antibiotic does not solve the bigger problem. We also look at who pays for the next generation of antibiotics, as World AMR Awareness Week continues.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, by Pharma Now, we look at an Ebola outbreak in the Democratic Republic of the Congo caused by a strain that has no approved vaccine or treatment made for it. The World Health Organization has just recommended adding two new vaccine candidates to a trial in the country, including one developed by Oxford with the Serum Institute of India. We explain how a vaccine trial works in the middle of an outbreak, why this strain is harder to fight, and what is still unknown. We also look at how cheaper malaria vaccines made in India could reach more children.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, by Pharma Now, we look at a cancer vaccine that is made from each patient’s own tumour and has just passed its biggest test so far. We explain how a vaccine can treat a cancer that is already there, what the trial showed, and why the result has been read in two very different ways. We also look at a new US approach that could make it easier to create gene-editing treatments for one patient at a time, and why that matters for who gets access to such medicines.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, we look at a draft rule from China that could stop its companies from selling the core toolkits behind some of the newest medicines to foreign buyers. These toolkits, called platforms, can turn out many drugs and not just one, which is why they matter so much. We explain what the draft says, what it still allows, and why law firms are already busy. We also look at a parallel move in Washington, and what the squeeze from both sides could mean for companies in India.
We’ll cover:
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
In this episode of Pharma Explained, by Pharma Now, we ask whether the United States is about to lose a public health title it has held for 25 years. An expert commission of the Pan American Health Organization has just reviewed whether the country still counts as having eliminated measles, and its recommendation is now with the organization’s director. We explain what “eliminated” really means, why it does not mean zero cases, and how experts use the virus’s genetic sequences to decide. We also look at where India stands on its own measles and rubella elimination target, which falls this year.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
Semaglutide, the ingredient behind weekly injections for diabetes and weight management, lost its main patent in India this year, and a dozen or so companies launched their own versions almost overnight. The seventh episode of Pharma Explained looks at what has changed for prices, brands and patients, and how the same patent expiry is playing out in other countries.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
Doctors in India are not allowed to accept gifts or sponsored foreign trips from pharma companies. But if the rules are broken, the doctor can lose a licence, while the company faces an industry-run process. In this episode of Pharma Explained, we look at who pays the price, and whether the law should reach companies too.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
The tablet may be made in India, but what about the ingredient inside it? Most people never ask who makes it, and the answer depends on how you count. In this episode of Pharma Explained, we look at where the key ingredient behind your medicine comes from, why so much of it traces back to one country, and what it means for you if that chain is ever disrupted.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
A cancer treatment that costs about $400,000 in the US is expected to cost around $50,000 in India. Can India and China make cell and gene therapy affordable, and will it ever reach patients outside the big cities? Today on Pharma Explained, by Pharma Now, we break it down.
We’ll cover:
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.
From the publisher's feed
Pharma moves fast. Prices get capped, factories get inspected, a new injection gets a nod from a regulator on the other side of the world. And somewhere in all of that is a person picking up a…
Pharma Explained by Pharma Now, is your morning briefing on what's changing in pharma and life sciences, in about six minutes. Every episode picks one story that matters, tells you what happened, how it actually works, and what it means for the person who takes the medicine. India first, with the world in the frame.